Dexamethasone Market by Route of Administration (Oral, Parenteral and Topical), Application (Asthma, Rheumatoid Arthritis, Skin Disorders, COVID-19, Allergic Disorder and Ulcerative Colitis), Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy) – Global Analysis & Forecast 2020-2030.

Report ID : 369  |  Published Date : Jul 2020  |  Pages : 160  |  Region : Global  |  Report Code : PH-25

Dexamethasone Market Overview and Introduction

Dexamethasone is a corticosteroid medication similar to a natural hormone produced by adrenal glands. It is used in a wide range of conditions for its anti-inflammatory and immunosuppressant effects. It relieves inflammation (swelling, heat, redness, and pain) and is used to treat certain forms of arthritis; skin, blood, kidney, eye, thyroid, & intestinal disorders (colitis); severe allergies; and asthma. It was also tested in hospitalized patients with COVID-19 in the clinical trial and was found to have benefits for critically ill patients.

The global dexamethasone market is primarily driven by growing prevalence of asthma and allergic diseases. Burgeoning demand of dexamethasone drug worldwide for the treatment of COVID-19 is playing a pivotal role in fuelling its uptake globally. However, issues with quality control and possibility of shortage of drug are likely to restrain market growth to a certain extent.

The global dexamethasone market has been analyzed from four perspective:  Route of Administration, Application, Distribution Channel, and Region.

Dexamethasone Market by Route of Administration

Based on route of administration, the market has been segmented into oral, parenteral and topical. The oral segment is expected to dominate the dexamethasone market during the forecast period owing to its ease & safety for self-administration. Additionally, long shelf life of tablets and efficient patient compliance is expected to further boost the market.

Dexamethasone Market by Application

Based on application, the market has been segmented into asthma, rheumatoid arthritis, skin disorders, COVID-19, allergic disorder, ulcerative colitis and others. The COVID-19 segment is expected to be the fastest-growing market for dexamethasone and is anticipated to contribute significantly to the global market share. In Jun 2019, a U.K based trial investigating potential Covid-19 treatments illustrated that dexamethasone can be lifesaving for patients who are critically ill and can reduce death rates by around a third among the most severely ill COVID-19 patients admitted to hospital. This has led to tremendous demand for the drug from all over world. Pharmaceutical companies have boosted the production capacity of dexamethasone drug to meet the colossal demand amid the outbreak of global pandemic COVID-19.  

Dexamethasone Market by Distribution Channel

Based on distribution channel, the market has been segmented into hospital pharmacy, retail pharmacy and online pharmacy. The hospital pharmacy segment is expected to dominate the dexamethasone market during the forecast period owing to surging hospital admissions for various diseased conditions, especially for COVID-19. Around 1 in every 5 people who are infected with COVID-19 suffers from difficulty in breathing requiring proper medication at hospital settings. This in turn is propelling its demand in the hospital setting.

Dexamethasone Market by Region

Based on region, the global dexamethasone market can be segmented into North America, Europe, Asia Pacific, and the Rest of the World (ROW). Asia Pacific region is expected to dominate the dexamethasone market during the forecast period. The growth in this region can be attributed to the presence of prominent players and growing export demand of the drug from around the world, owing to its positive effects in the treatment of COVID-19.

Dexamethasone Market Prominent Players

Some of the prominent players operating in the dexamethasone market include Allergan, Ocular Therapeutix, Inc., Zydus Cadila, Cadila Pharmaceuticals, Fresenius Kabi USA, GLS pharma ltd, Pfizer Limited, Novartis AG, Mylan N.V. Sun Pharmaceutical Industries Ltd., among others.